Drug-like properties: concepts, structure design and methods : from ADME to toxicity optimization
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Amsterdam
Academic Press
c2008
|
| Schlagworte: | |
| Online-Zugang: | FUBA1 Volltext |
| Beschreibung: | Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug discovery. If the properties are weak, the candidate will have a high risk of failure or be less desirable as a drug product. This book is a tool and resource for scientists engaged in, or preparing for, the selection and optimization process. The authors describe how properties affect in vivo pharmacological activity and impact in vitro assays. Individual drug-like properties are discussed from a practical point of view, such as solubility, permeability and metabolic stability, with regard to fundamental understanding, applications of property data in drug discovery and examples of structural modifications that have achieved improved property performance. The authors also review various methods for the screening (high throughput), diagnosis (medium throughput) and in-depth (low throughput) analysis of drug properties. * Serves as an essential working handbook aimed at scientists and students in medicinal chemistry * Provides practical, step-by-step guidance on property fundamentals, effects, structure-property relationships, and structure modification strategies * Discusses improvements in pharmacokinetics from a practical chemist's standpoint Includes bibliographical references (p. 492) and index |
| Beschreibung: | 1 Online-Ressource (xix, 526 p., [2] p. of plates) |
| ISBN: | 9780123695208 0123695201 9780080557618 0080557619 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV042307301 | ||
| 003 | DE-604 | ||
| 005 | 20180119 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 150129s2008 |||| o||u| ||||||eng d | ||
| 020 | |a 9780123695208 |c Online |9 978-0-12-369520-8 | ||
| 020 | |a 0123695201 |9 0-12-369520-1 | ||
| 020 | |a 9780080557618 |c electronic bk. |9 978-0-08-055761-8 | ||
| 020 | |a 0080557619 |c electronic bk. |9 0-08-055761-9 | ||
| 035 | |a (OCoLC)281596284 | ||
| 035 | |a (DE-599)BVBBV042307301 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-188 | ||
| 082 | 0 | |a 615/.19 |2 22 | |
| 100 | 1 | |a Kerns, Edward Harvel |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Drug-like properties |b concepts, structure design and methods : from ADME to toxicity optimization |c Edward H. Kerns and Li Di |
| 264 | 1 | |a Amsterdam |b Academic Press |c c2008 | |
| 300 | |a 1 Online-Ressource (xix, 526 p., [2] p. of plates) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug discovery. If the properties are weak, the candidate will have a high risk of failure or be less desirable as a drug product. This book is a tool and resource for scientists engaged in, or preparing for, the selection and optimization process. The authors describe how properties affect in vivo pharmacological activity and impact in vitro assays. Individual drug-like properties are discussed from a practical point of view, such as solubility, permeability and metabolic stability, with regard to fundamental understanding, applications of property data in drug discovery and examples of structural modifications that have achieved improved property performance. The authors also review various methods for the screening (high throughput), diagnosis (medium throughput) and in-depth (low throughput) analysis of drug properties. * Serves as an essential working handbook aimed at scientists and students in medicinal chemistry * Provides practical, step-by-step guidance on property fundamentals, effects, structure-property relationships, and structure modification strategies * Discusses improvements in pharmacokinetics from a practical chemist's standpoint | ||
| 500 | |a Includes bibliographical references (p. 492) and index | ||
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Drugs / Design |2 fast | |
| 650 | 7 | |a Drugs / Structure-activity relationships |2 fast | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Drug Evaluation, Preclinical | |
| 650 | 4 | |a Drug-Related Side Effects and Adverse Reactions | |
| 650 | 4 | |a Pharmaceutical Preparations / metabolism | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 4 | |a Structure-Activity Relationship | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Pharmaceutical chemistry | |
| 650 | 4 | |a Drugs |x Structure-activity relationships | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Drugs |x Design | |
| 650 | 0 | 7 | |a Wirkungsmechanismus |0 (DE-588)4292866-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Konzeption |0 (DE-588)4204973-8 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | 1 | |a Konzeption |0 (DE-588)4204973-8 |D s |
| 689 | 0 | 2 | |a Wirkungsmechanismus |0 (DE-588)4292866-7 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Di, Li |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/book/9780123695208 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-33-ESD |a ZDB-33-EBS | ||
| 940 | 1 | |q FAW_PDA_ESD | |
| 940 | 1 | |q FLA_PDA_ESD | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-027744293 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u http://www.sciencedirect.com/science/book/9780123695208 |l FUBA1 |p ZDB-33-ESD |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804152892408463360 |
|---|---|
| any_adam_object | |
| author | Kerns, Edward Harvel |
| author_facet | Kerns, Edward Harvel |
| author_role | aut |
| author_sort | Kerns, Edward Harvel |
| author_variant | e h k eh ehk |
| building | Verbundindex |
| bvnumber | BV042307301 |
| collection | ZDB-33-ESD ZDB-33-EBS |
| ctrlnum | (OCoLC)281596284 (DE-599)BVBBV042307301 |
| dewey-full | 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.19 |
| dewey-search | 615/.19 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04357nmm a2200721zc 4500</leader><controlfield tag="001">BV042307301</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20180119 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">150129s2008 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780123695208</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-12-369520-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0123695201</subfield><subfield code="9">0-12-369520-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780080557618</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-08-055761-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0080557619</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-08-055761-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)281596284</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042307301</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-188</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield><subfield code="2">22</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kerns, Edward Harvel</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug-like properties</subfield><subfield code="b">concepts, structure design and methods : from ADME to toxicity optimization</subfield><subfield code="c">Edward H. Kerns and Li Di</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam</subfield><subfield code="b">Academic Press</subfield><subfield code="c">c2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xix, 526 p., [2] p. of plates)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug discovery. If the properties are weak, the candidate will have a high risk of failure or be less desirable as a drug product. This book is a tool and resource for scientists engaged in, or preparing for, the selection and optimization process. The authors describe how properties affect in vivo pharmacological activity and impact in vitro assays. Individual drug-like properties are discussed from a practical point of view, such as solubility, permeability and metabolic stability, with regard to fundamental understanding, applications of property data in drug discovery and examples of structural modifications that have achieved improved property performance. The authors also review various methods for the screening (high throughput), diagnosis (medium throughput) and in-depth (low throughput) analysis of drug properties. * Serves as an essential working handbook aimed at scientists and students in medicinal chemistry * Provides practical, step-by-step guidance on property fundamentals, effects, structure-property relationships, and structure modification strategies * Discusses improvements in pharmacokinetics from a practical chemist's standpoint</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (p. 492) and index</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Design</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Structure-activity relationships</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical chemistry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation, Preclinical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug-Related Side Effects and Adverse Reactions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical Preparations / metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacokinetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Structure-Activity Relationship</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical chemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Structure-activity relationships</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkungsmechanismus</subfield><subfield code="0">(DE-588)4292866-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Konzeption</subfield><subfield code="0">(DE-588)4204973-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Konzeption</subfield><subfield code="0">(DE-588)4204973-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Wirkungsmechanismus</subfield><subfield code="0">(DE-588)4292866-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di, Li</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/book/9780123695208</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-33-ESD</subfield><subfield code="a">ZDB-33-EBS</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">FAW_PDA_ESD</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">FLA_PDA_ESD</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-027744293</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.sciencedirect.com/science/book/9780123695208</subfield><subfield code="l">FUBA1</subfield><subfield code="p">ZDB-33-ESD</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV042307301 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T01:17:56Z |
| institution | BVB |
| isbn | 9780123695208 0123695201 9780080557618 0080557619 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-027744293 |
| oclc_num | 281596284 |
| open_access_boolean | |
| owner | DE-1046 DE-188 |
| owner_facet | DE-1046 DE-188 |
| physical | 1 Online-Ressource (xix, 526 p., [2] p. of plates) |
| psigel | ZDB-33-ESD ZDB-33-EBS FAW_PDA_ESD FLA_PDA_ESD |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Academic Press |
| record_format | marc |
| spelling | Kerns, Edward Harvel Verfasser aut Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization Edward H. Kerns and Li Di Amsterdam Academic Press c2008 1 Online-Ressource (xix, 526 p., [2] p. of plates) txt rdacontent c rdamedia cr rdacarrier Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug discovery. If the properties are weak, the candidate will have a high risk of failure or be less desirable as a drug product. This book is a tool and resource for scientists engaged in, or preparing for, the selection and optimization process. The authors describe how properties affect in vivo pharmacological activity and impact in vitro assays. Individual drug-like properties are discussed from a practical point of view, such as solubility, permeability and metabolic stability, with regard to fundamental understanding, applications of property data in drug discovery and examples of structural modifications that have achieved improved property performance. The authors also review various methods for the screening (high throughput), diagnosis (medium throughput) and in-depth (low throughput) analysis of drug properties. * Serves as an essential working handbook aimed at scientists and students in medicinal chemistry * Provides practical, step-by-step guidance on property fundamentals, effects, structure-property relationships, and structure modification strategies * Discusses improvements in pharmacokinetics from a practical chemist's standpoint Includes bibliographical references (p. 492) and index MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Drug development fast Drugs / Design fast Drugs / Structure-activity relationships fast Pharmaceutical chemistry fast Drug Design Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions Pharmaceutical Preparations / metabolism Pharmacokinetics Structure-Activity Relationship Medizin Pharmaceutical chemistry Drugs Structure-activity relationships Drug development Drugs Design Wirkungsmechanismus (DE-588)4292866-7 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf Konzeption (DE-588)4204973-8 gnd rswk-swf Arzneimittel (DE-588)4003115-9 s Konzeption (DE-588)4204973-8 s Wirkungsmechanismus (DE-588)4292866-7 s 1\p DE-604 Di, Li Sonstige oth http://www.sciencedirect.com/science/book/9780123695208 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Kerns, Edward Harvel Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Drug development fast Drugs / Design fast Drugs / Structure-activity relationships fast Pharmaceutical chemistry fast Drug Design Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions Pharmaceutical Preparations / metabolism Pharmacokinetics Structure-Activity Relationship Medizin Pharmaceutical chemistry Drugs Structure-activity relationships Drug development Drugs Design Wirkungsmechanismus (DE-588)4292866-7 gnd Arzneimittel (DE-588)4003115-9 gnd Konzeption (DE-588)4204973-8 gnd |
| subject_GND | (DE-588)4292866-7 (DE-588)4003115-9 (DE-588)4204973-8 |
| title | Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization |
| title_auth | Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization |
| title_exact_search | Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization |
| title_full | Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization Edward H. Kerns and Li Di |
| title_fullStr | Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization Edward H. Kerns and Li Di |
| title_full_unstemmed | Drug-like properties concepts, structure design and methods : from ADME to toxicity optimization Edward H. Kerns and Li Di |
| title_short | Drug-like properties |
| title_sort | drug like properties concepts structure design and methods from adme to toxicity optimization |
| title_sub | concepts, structure design and methods : from ADME to toxicity optimization |
| topic | MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Drug development fast Drugs / Design fast Drugs / Structure-activity relationships fast Pharmaceutical chemistry fast Drug Design Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions Pharmaceutical Preparations / metabolism Pharmacokinetics Structure-Activity Relationship Medizin Pharmaceutical chemistry Drugs Structure-activity relationships Drug development Drugs Design Wirkungsmechanismus (DE-588)4292866-7 gnd Arzneimittel (DE-588)4003115-9 gnd Konzeption (DE-588)4204973-8 gnd |
| topic_facet | MEDICAL / Drug Guides MEDICAL / Pharmacology MEDICAL / Pharmacy MEDICAL / Nursing / Pharmacology Drug development Drugs / Design Drugs / Structure-activity relationships Pharmaceutical chemistry Drug Design Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions Pharmaceutical Preparations / metabolism Pharmacokinetics Structure-Activity Relationship Medizin Drugs Structure-activity relationships Drugs Design Wirkungsmechanismus Arzneimittel Konzeption |
| url | http://www.sciencedirect.com/science/book/9780123695208 |
| work_keys_str_mv | AT kernsedwardharvel druglikepropertiesconceptsstructuredesignandmethodsfromadmetotoxicityoptimization AT dili druglikepropertiesconceptsstructuredesignandmethodsfromadmetotoxicityoptimization |